Scholarlink

<p>Intraoperative remifentanil reduces postoperative delirium incidence, unlike other opioids; however, its efficacy in medical emergencies with organ failure is unknown. We hypothesized that remifentanil use in nonoperative intensive care unit (ICU) patients requiring ventilatory management would improve delirium outcomes. This retrospective study included 95 nonoperative patients with unplanned ICU admissions requiring ventilatory opioids. Delirium was assessed using the Intensive Care Delirium Screening Checklist. Patients were divided into remifentanil and non-remifentanil groups; statistical adjustments were made using propensity score matching and inverse probability weighting. After matching, the remifentanil group had significantly more delirium-free days (DFDs) within 14&#xa0;days than the non-remifentanil group (8 [5–11] vs. 5 [3–9], <i>p</i> &lt; .001). Adjusted multivariate analysis showed that DFD was significantly increased in the remifentanil group (Odds ratio = 2.639 [95% CI 1.279–5.445]; <i>p</i> = 0.009). Remifentanil use in nonoperative ventilated ICU patients may reduce delirium duration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Remifentanil use in critically Ill patients requiring mechanical ventilation is associated with increased delirium-free days: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月19日

查看全文
  • Junpei Haruna,
  • Aki Sasaki,
  • Satoshi Kazuma

摘要

Intraoperative remifentanil reduces postoperative delirium incidence, unlike other opioids; however, its efficacy in medical emergencies with organ failure is unknown. We hypothesized that remifentanil use in nonoperative intensive care unit (ICU) patients requiring ventilatory management would improve delirium outcomes. This retrospective study included 95 nonoperative patients with unplanned ICU admissions requiring ventilatory opioids. Delirium was assessed using the Intensive Care Delirium Screening Checklist. Patients were divided into remifentanil and non-remifentanil groups; statistical adjustments were made using propensity score matching and inverse probability weighting. After matching, the remifentanil group had significantly more delirium-free days (DFDs) within 14 days than the non-remifentanil group (8 [5–11] vs. 5 [3–9], p < .001). Adjusted multivariate analysis showed that DFD was significantly increased in the remifentanil group (Odds ratio = 2.639 [95% CI 1.279–5.445]; p = 0.009). Remifentanil use in nonoperative ventilated ICU patients may reduce delirium duration.